in a prospective , placebo-controlled study , 74 women with recurrent vulvovaginal candidiasis were treated with oral ketoconazole ( 400 mg daily for two weeks ) and were then randomly assigned to receive placebo ( group a ) , prophylactic ketoconazole , 400 mg daily for five days beginning with the onset of menses for six menstrual cycles ( group b ) , or low-dose ketoconazole , 100 mg daily for six months ( group c ) .
C0700345
vulvovaginal
C0022625
ketoconazole